The approach most advanced in preclinical and clinical studies is targeting the HIV-1 co-receptor, CCR5, via naturally mutated or engineered hematopoietic stem cells (HSCs) and rendering the cells resistant to HIV-1 infection after gene-modified HSC transplant. The gene discussed is CCR5; the disease is HIV-1 infection.